See more : Contact Energy Limited (COENF) Income Statement Analysis – Financial Results
Complete financial analysis of La Jolla Pharmaceutical Company (LJPC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of La Jolla Pharmaceutical Company, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Golden Star Enterprises Ltd. (GSPT) Income Statement Analysis – Financial Results
- Okinawa Cellular Telephone Company (OKCTF) Income Statement Analysis – Financial Results
- Fuchs Petrolub SE (FPE3.DE) Income Statement Analysis – Financial Results
- JIG-SAW INC. (3914.T) Income Statement Analysis – Financial Results
- Loblaw Companies Limited (L-PB.TO) Income Statement Analysis – Financial Results
La Jolla Pharmaceutical Company (LJPC)
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. As of August 22, 2022, La Jolla Pharmaceutical Company operates as a subsidiary of Innoviva, Inc.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 75.72M | 33.42M | 23.05M | 10.06M | 0.00 | 616.00K | 1.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.13M | 0.00 | 55.11M | 35.76M | 35.76M | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 4.69M | 8.60M | 9.90M | 4.00M | 3.00M | 600.00K |
| Cost of Revenue | 13.49M | 7.82M | 2.39M | 1.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -381.00K | -357.00K | -400.00K | -800.00K | -800.00K | -800.00K | -700.00K |
| Gross Profit | 62.23M | 25.60M | 20.66M | 8.41M | 0.00 | 616.00K | 1.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.13M | 0.00 | 55.11M | 35.76M | 35.76M | 0.00 | 0.00 | 0.00 | 0.00 | 382.00K | 5.05M | 9.00M | 10.70M | 4.80M | 3.80M | 1.30M |
| Gross Profit Ratio | 82.19% | 76.60% | 89.62% | 83.66% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 38,200.00% | 107.61% | 104.65% | 108.08% | 120.00% | 126.67% | 216.67% |
| Research & Development | 5.01M | 23.01M | 85.33M | 117.30M | 84.58M | 62.29M | 29.09M | 9.94M | 4.36M | 1.35M | 177.00K | 13.00K | 9.58M | 51.03M | 46.64M | 32.94M | 22.60M | 33.17M | 32.39M | 37.70M | 23.23M | 12.93M | 11.69M | 14.60M | 14.70M | 11.70M | 9.80M | 8.50M |
| General & Administrative | 29.77M | 34.51M | 37.94M | 61.23M | 30.85M | 16.70M | 13.93M | 11.40M | 13.58M | 9.39M | 2.10M | 0.00 | 0.00 | 9.70M | 0.00 | 0.00 | 0.00 | 7.57M | 6.91M | 6.94M | 4.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 5.62M | 3.92M | 7.19M | 23.93M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 35.39M | 38.43M | 45.13M | 85.16M | 30.85M | 16.70M | 13.93M | 11.40M | 13.58M | 9.39M | 2.10M | 3.92M | 7.19M | 9.70M | 9.06M | 9.29M | 5.41M | 7.57M | 6.91M | 6.94M | 4.27M | 2.71M | 2.94M | 3.10M | 2.90M | 2.90M | 2.40M | 2.00M |
| Other Expenses | 8.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 381.00K | 357.00K | 400.00K | 800.00K | 800.00K | 800.00K | 700.00K |
| Operating Expenses | 40.40M | 61.44M | 130.46M | 202.46M | 115.43M | 78.99M | 43.03M | 21.34M | 17.94M | 10.74M | 2.27M | 3.93M | 16.77M | 60.73M | 55.69M | 42.23M | 28.00M | 40.74M | 39.29M | 44.64M | 27.50M | 16.02M | 14.99M | 18.10M | 18.40M | 15.40M | 13.00M | 11.20M |
| Cost & Expenses | 53.89M | 69.26M | 132.86M | 204.11M | 115.43M | 78.99M | 43.03M | 21.34M | 17.94M | 10.74M | 2.27M | 3.93M | 16.77M | 60.73M | 55.69M | 42.23M | 28.00M | 40.74M | 39.29M | 44.64M | 27.50M | 15.64M | 14.63M | 17.70M | 17.60M | 14.60M | 12.20M | 10.50M |
| Interest Income | 7.00K | 235.00K | 2.13M | 1.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 779.00K | 0.00 | 0.00 | 0.00 | 383.00K | 665.00K | 1.37M | 2.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 10.46M | 10.05M | 10.77M | 7.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.00K | 96.00K | 0.00 | 0.00 | 0.00 | -190.00K | -210.00K | -51.00K | -30.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.88M | 4.08M | 4.55M | 4.41M | 1.27M | 730.00K | 347.00K | 17.00K | 5.00K | 3.00M | -9.27M | 168.00K | 117.00K | 990.00K | 1.69M | 1.99M | 2.11M | 2.08M | 1.92M | 1.39M | 684.00K | 381.00K | 357.00K | 400.00K | 800.00K | 800.00K | 800.00K | 700.00K |
| EBITDA | 32.05M | -35.84M | -109.80M | -187.76M | -115.43M | -78.37M | -41.97M | -21.34M | -17.94M | -7.74M | -11.55M | -3.76M | -8.50M | -63.54M | -55.69M | -28.00M | -28.00M | -38.46M | -36.92M | -44.64M | -27.50M | -13.42M | -8.79M | -7.50M | -5.60M | -8.80M | -7.80M | -9.60M |
| EBITDA Ratio | 42.32% | -75.66% | -438.89% | -1,867.15% | 0.00% | -12,573.86% | -3,932.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -104.66% | 0.00% | -93.25% | -104.76% | -70.63% | 0.00% | 0.00% | 0.00% | 0.00% | -1,341,800.00% | -187.46% | -87.21% | -56.57% | -220.00% | -260.00% | -1,600.00% |
| Operating Income | 30.17M | -35.84M | -109.80M | -194.05M | -115.43M | -78.37M | -41.97M | -21.34M | -17.94M | -10.74M | -2.27M | -3.93M | -8.64M | -63.54M | -55.69M | -42.23M | -28.00M | -40.74M | -39.29M | -44.64M | -27.50M | -15.64M | -9.94M | -9.10M | -7.70M | -10.60M | -9.20M | -9.90M |
| Operating Income Ratio | 39.84% | -107.24% | -476.28% | -1,929.70% | 0.00% | -12,722.73% | -3,970.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -106.39% | 0.00% | -101.06% | -118.10% | -78.32% | 0.00% | 0.00% | 0.00% | 0.00% | -1,563,800.00% | -211.94% | -105.81% | -77.78% | -265.00% | -306.67% | -1,650.00% |
| Total Other Income/Expenses | -2.12M | -3.58M | -6.71M | -5.42M | 624.00K | 187.00K | 57.00K | 27.00K | 4.00K | 3.00M | -9.39M | 168.00K | 10.00K | 683.00K | 2.62M | 640.00K | 640.00K | 193.00K | 455.00K | 1.32M | 2.81M | 0.00 | 0.00 | 1.20M | 1.40M | 1.20M | 900.00K | 0.00 |
| Income Before Tax | 19.71M | -39.42M | -116.51M | -199.47M | -114.80M | -78.19M | -41.91M | -21.31M | -17.94M | -7.74M | -11.67M | -3.76M | -62.85M | -62.85M | -53.08M | -27.36M | -27.36M | -40.54M | -38.84M | -43.32M | -24.68M | 0.00 | 0.00 | -7.90M | -6.30M | -9.40M | -8.30M | 0.00 |
| Income Before Tax Ratio | 26.03% | -117.96% | -505.37% | -1,983.58% | 0.00% | -12,692.37% | -3,965.18% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -773.59% | 0.00% | -96.31% | -76.53% | -76.53% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -91.86% | -63.64% | -235.00% | -276.67% | 0.00% |
| Income Tax Expense | 49.00K | 6.47M | 4.07M | 1.89M | 624.00K | 187.00K | 57.00K | 27.00K | 4.00K | 0.00 | 0.00 | 0.00 | 36.00K | -2.71M | 2.62M | 14.86M | 640.00K | 193.00K | 455.00K | 1.32M | 2.81M | 0.00 | 0.00 | 1.20M | 1.40M | 1.20M | 900.00K | 0.00 |
| Net Income | 19.66M | -39.42M | -116.51M | -199.47M | -114.80M | -78.19M | -41.91M | -21.31M | -17.94M | -7.74M | -11.55M | -3.76M | -8.63M | -62.85M | -53.08M | -39.45M | -27.36M | -40.54M | -38.84M | -43.32M | -24.68M | -13.80M | -9.15M | -7.90M | -6.40M | -9.60M | -8.60M | -10.30M |
| Net Income Ratio | 25.96% | -117.96% | -505.37% | -1,983.58% | 0.00% | -12,692.37% | -3,965.18% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -106.26% | 0.00% | -96.31% | -110.32% | -76.53% | 0.00% | 0.00% | 0.00% | 0.00% | -1,379,900.00% | -195.07% | -91.86% | -64.65% | -240.00% | -286.67% | -1,716.67% |
| EPS | 0.58 | -1.44 | -4.30 | -7.85 | -5.41 | -4.54 | -2.68 | -2.00 | -39.48 | -37.94 | -1.56K | -19.89K | -65.91K | -566.25K | -671.85K | -606.85K | -420.97K | -1.62M | -1.94M | -2.71M | -1.76M | -1.25M | -1.14M | -987.50K | -914.29K | -1.60M | -1.72M | -3.43M |
| EPS Diluted | 0.58 | -1.44 | -4.30 | -7.85 | -5.41 | -4.54 | -2.68 | -2.00 | -39.48 | -37.94 | -1.56K | -19.89K | -65.91K | -566.25K | -671.85K | -606.85K | -420.97K | -1.62M | -1.94M | -2.71M | -1.76M | -1.25M | -1.14M | -987.50K | -914.29K | -1.60M | -1.72M | -3.43M |
| Weighted Avg Shares Out | 34.18M | 27.33M | 27.11M | 25.42M | 21.22M | 17.23M | 15.65M | 10.67M | 454.34K | 203.92K | 7.38K | 189.00 | 131.00 | 111.00 | 79.00 | 65.00 | 65.00 | 25.00 | 20.00 | 16.00 | 14.00 | 11.00 | 8.00 | 8.00 | 7.00 | 6.00 | 5.00 | 3.00 |
| Weighted Avg Shares Out (Dil) | 34.18M | 27.33M | 27.11M | 25.42M | 21.22M | 17.23M | 15.65M | 10.67M | 454.34K | 203.92K | 7.38K | 189.00 | 131.00 | 111.00 | 79.00 | 65.00 | 65.00 | 25.00 | 20.00 | 16.00 | 14.00 | 11.00 | 8.00 | 8.00 | 7.00 | 6.00 | 5.00 | 3.00 |
Innoviva Completes Acquisition of La Jolla Pharmaceutical
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of...
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating La Jolla Pharmaceuticals Company Buyout
Wilmington, Delaware--(Newsfile Corp. - July 12, 2022) - Rigrodsky Law, P.A. is investigating La Jolla Pharmaceuticals Company ("La Jolla") (NASDAQ: LJPC) regarding possible breaches of fiduciary duties and other violations of law related to La Jolla's agreement to be acquired...
SHAREHOLDER ALERT: Weiss Law Investigates La Jolla Pharmaceutical Company
NEW YORK , July 11, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of La Jolla Pharmaceutical Company ("La Jolla" or the "Company") (NASDAQ: LJPC) in connection with...
La Jolla Pharmaceutical Company (LJPC) Stock: Why It Skyrocketed Over 80% Today
The stock price of La Jolla Pharmaceutical Company (NASDAQ: LJPC) surged by over 80% during intraday trading today. This is why.
Innoviva to Acquire La Jolla Pharmaceutical Company
BURLINGAME, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of...
Moving Average Crossover Alert: La Jolla Pharmaceutical (LJPC)
La Jolla Pharmaceutical (LJPC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
La Jolla Pharmaceutical (LJPC) Misses Q1 Earnings Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -37.31% and 2.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Corporate Progress
WALTHAM, Mass.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2021...
La Jolla Pharmaceutical (LJPC) Reports Q4 Loss, Tops Revenue Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 62.86% and 7.68%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Source: https://incomestatements.info
Category: Stock Reports